APA (7th ed.) Citation

M, P., C, M., M, L., E, A., P, d. B., R, B., . . . P, D. (2021). Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: Pooled 52-week outcomes from the DEPICT-1 and -2 studies. Diabetes, obesity & metabolism, 23(2), 549. https://doi.org/10.1111/dom.14248

Chicago Style (17th ed.) Citation

M, Phillip, et al. "Long-term Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes: Pooled 52-week Outcomes from the DEPICT-1 and -2 Studies." Diabetes, Obesity & Metabolism 23, no. 2 (2021): 549. https://doi.org/10.1111/dom.14248.

MLA (9th ed.) Citation

M, Phillip, et al. "Long-term Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes: Pooled 52-week Outcomes from the DEPICT-1 and -2 Studies." Diabetes, Obesity & Metabolism, vol. 23, no. 2, 2021, p. 549, https://doi.org/10.1111/dom.14248.